BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 33428899)

  • 1. Antiproliferative effect, alteration of cancer cell cycle progression and potential MET kinase inhibition induced by 3,4-dihydropyrimidin-2(1H)-one C5 amide derivatives.
    Moosavi F; Ebadi A; Mohabbati M; Damghani T; Mortazavi M; Miri R; Firuzi O
    Eur J Pharmacol; 2021 Mar; 894():173850. PubMed ID: 33428899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases including c-Met.
    Damghani T; Moosavi F; Khoshneviszadeh M; Mortazavi M; Pirhadi S; Kayani Z; Saso L; Edraki N; Firuzi O
    Sci Rep; 2021 Feb; 11(1):3644. PubMed ID: 33574356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of anticancer agents with c-Met inhibitory potential by virtual and experimental screening of a chemical library.
    Mortazavi M; Raufi E; Damghani T; Khoshneviszadeh M; Edraki N; Eskandari M; Giovannetti E; Peters GJ; Pirhadi S; Firuzi O
    Eur J Pharmacol; 2023 Jan; 938():175395. PubMed ID: 36410418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
    Zhu W; Wang W; Xu S; Wang J; Tang Q; Wu C; Zhao Y; Zheng P
    Bioorg Med Chem; 2016 Apr; 24(8):1749-56. PubMed ID: 26964675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and Anti-Proliferative Evaluations of New Heterocyclic Derivatives Using 5,6,8,9-Tetrahydropyrazolo[5,1-b]quinazolin-7(3H)-one Derivatives Derived from Cyclohexa-1,4-dione.
    Mahmoud MAA; Alsharif MA; Mohareb RM
    Anticancer Agents Med Chem; 2021; 21(4):468-486. PubMed ID: 32445457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and bioevaluation and doking study of 1H-pyrrolo[2,3-b]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors.
    Wang W; Xu S; Duan Y; Liu X; Li X; Wang C; Zhao B; Zheng P; Zhu W
    Eur J Med Chem; 2018 Feb; 145():315-327. PubMed ID: 29331754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors.
    Li S; Zhao Y; Wang K; Gao Y; Han J; Cui B; Gong P
    Bioorg Med Chem; 2013 Jun; 21(11):2843-55. PubMed ID: 23628470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions.
    Nan X; Li HJ; Fang SB; Li QY; Wu YC
    Eur J Med Chem; 2020 May; 193():112241. PubMed ID: 32200199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of novel N-[4-(2-fluorophenoxy)pyridin-2-yl]cyclopropanecarboxamide derivatives as potential c-Met kinase inhibitors.
    Liu J; Gong Y; Shi J; Hao X; Wang Y; Zhou Y; Hou Y; Liu Y; Ding S; Chen Y
    Eur J Med Chem; 2020 May; 194():112244. PubMed ID: 32224380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of novel N-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction.
    Nan X; Zhang J; Li HJ; Wu R; Fang SB; Zhang ZZ; Wu YC
    Eur J Med Chem; 2020 Aug; 200():112470. PubMed ID: 32505087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a novel 6,7-disubstituted-4-(2-fluorophenoxy)quinolines bearing 1,2,3-triazole-4-carboxamide moiety as potent c-Met kinase inhibitors.
    Liu M; Hou Y; Yin W; Zhou S; Qian P; Guo Z; Xu L; Zhao Y
    Eur J Med Chem; 2016 Aug; 119():96-108. PubMed ID: 27155466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, Synthesis and Biological Evaluation of Novel 4-phenoxypyridine Derivatives Containing Semicarbazones Moiety as Potential c-Met Kinase Inhibitors.
    Li J; Li J; Zhang J; Shi J; Ding S; Liu Y; Chen Y; Liu J
    Anticancer Agents Med Chem; 2020; 20(5):559-570. PubMed ID: 31893997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel 7-azaindole derivatives bearing dihydropyridazine moiety as c-Met kinase inhibitors.
    Tang Q; Wang L; Duan Y; Wang W; Huang S; Zhi J; Jia S; Zhu W; Wang P; Luo R; Zheng P
    Eur J Med Chem; 2017 Jun; 133():97-106. PubMed ID: 28384549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Design and Synthesis of New 3,4-Dihydropyrimidin-2(1H)-Ones as Potential Anticancer Agents with VEGFR-2 Inhibiting Activity.
    Mostafa AS; Bayoumi WA; El-Mesery M; Elgaml A
    Anticancer Agents Med Chem; 2019; 19(3):310-322. PubMed ID: 30019649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and antitumor evaluation of novel 5-methylpyrazolo[1,5-a]pyrimidine derivatives as potential c-Met inhibitors.
    Luo G; Ma Y; Liang X; Xie G; Luo Y; Zha D; Wang S; Yu L; Zheng X; Wu W; Zhang C
    Bioorg Chem; 2020 Nov; 104():104356. PubMed ID: 33142417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and molecular modeling studies of new series of antitumor 1,2,4-triazines with potential c-Met kinase inhibitory activity.
    El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
    Bioorg Chem; 2018 Feb; 76():154-165. PubMed ID: 29175587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and Synthesis of Novel 4-Phenoxyquinolines Bearing 3-Hydrosulfonylacrylamido or 1H-Imidazole-4-carboxamido Scaffolds as c-Met Kinase Inhibitors.
    Wang J; Xie L; Wang Y; Wang X; Xi S; Zeng T; Gong P; Zhai X
    Arch Pharm (Weinheim); 2017 Feb; 350(2):. PubMed ID: 28133784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Target identification, lead optimization and antitumor evaluation of some new 1,2,4-triazines as c-Met kinase inhibitors.
    El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
    Bioorg Chem; 2017 Aug; 73():154-169. PubMed ID: 28715754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
    Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
    Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and bioevaluation study of novel N-methylpicolinamide and thienopyrimidine derivatives as selectivity c-Met kinase inhibitors.
    Wang L; Xu S; Chen X; Liu X; Duan Y; Kong D; Zhao D; Zheng P; Tang Q; Zhu W
    Bioorg Med Chem; 2018 Jan; 26(1):245-256. PubMed ID: 29203143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.